Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03984383

IL-33, Endocan and Endothelial Cells

Regulation of IL33, Endocan and Their Targets in Primary Human Endothelial Cells

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study aims to investigate the inflammatory response of endothelial cells to various stimulations, in particular the production of IL33 and of endocan in response to allergens, agonists of microorganisms and pollutants. For that purpose, this project attempts to set up a biological collection of lung and umbilical cord endothelial cells. Lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer surgery. Umbilical cord-derived endothelial cells are taken from the umbilical cord collected during the delivery.

Conditions

Timeline

Start date
2021-11-08
Primary completion
2021-11-08
Completion
2021-11-08
First posted
2019-06-13
Last updated
2022-11-04

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03984383. Inclusion in this directory is not an endorsement.

IL-33, Endocan and Endothelial Cells (NCT03984383) · Clinical Trials Directory